Actions
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
2
Neutral
7
Bullish
5
Bearish
17
Neutral
7
Bullish
22
Bearish
15
Neutral
0
Bullish
17
Bearish
15
Neutral
0
Bullish
17
Bearish
15
Neutral
0
Bullish
17
Bearish
15
Neutral
0
Bullish
17
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone

Healthcare Equipment & Supplies
Medical Equipment & Supplies
16,913 Cr
Low Risk
53.48
60.46
1.98
5.18
2,022.00
1,184.00
Sales CAGR
Profit CAGR
ROE
ROCE
Poly Medicure Ltd (POLYMED) is currently trading at 1,630.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Poly Medicure Limited manufactures and supplies medical devices across infusion therapy, dialysis, blood management, critical care, orthopaedics, cardiology, surgery and related healthcare segments, serving domestic and international markets through a multi-country manufacturing and distribution network. Standalone H1 FY27 revenue increased 15% to INR919 crore, while operating EBITDA grew 20% to INR255 crore. Despite raw-material inflation, freight disruption and geopolitical pressure, gross margin expanded 111 basis points to 70.1%, demonstrating pricing actions, inventory management and a favourable product mix. Consolidated H1 FY27 revenue rose 31% to INR1,106 crore, although organic growth was 14% excluding acquisitions. Europe recovered sharply, growing 29% organically in H1 and approximately 40% in Q2, supported by new customers, deeper engagement and normalization of prior inventory-related challenges. Poly Medicure Limited is building a broader international platform through new subsidiaries in Brazil and the United Kingdom, while targeting U.S. sales of approximately USD7–8 million in FY27. The company expects further expansion through product approvals, European registrations and projects linked to India–UK and India–EU trade opportunities. The company maintains a strong liquidity position, with INR839 crore of consolidated liquidity against INR377 crore of debt and reported net cash of INR460 crore. Management reaffirmed FY27 consolidated revenue guidance of INR2,300–2,400 crore and standalone EBITDA margin guidance of 26–27.5%.
Over the past 52 weeks, Poly Medicure Ltd has traded between a low of ₹1,184.00 and a high of ₹2,022.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Poly Medicure Ltd has a market capitalization of approximately 16,912.67. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Poly Medicure Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 53.48 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 16,912.67 Cr, Poly Medicure Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Poly Medicure Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Poly Medicure Ltd is 53.48. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Polymed said its European business grew close to 40% organically in Q2 FY27. The company reported 29% organic growth for Europe in H1 FY27, indicating that the second-quarter pace exceeded the half-year average.
Poly Medicure said the DGHS notification requires medical devices to be used only one time. Management highlighted dialyzers because they had previously been reused four to five times despite being designed for single use.
Polymed said PendraCare’s EBITDA loss resulted primarily from higher raw-material costs and disruption to Middle East sales. The Middle East represented close to 20% of PendraCare’s 2025 revenue and included meaningful exposure to Iran. Management said the logistics disruption, rather than weaker underlying demand, was the central sales issue.
Poly Medicure raised standalone FY27 EBITDA-margin guidance to 26%-27.5% from 25%-27%. Its consolidated FY27 EBITDA-margin guidance remains 23%-25%.
